Fig. 4

WT1-AS was a negative regulator for chemo-resistance though JAK2/STAT3 and MAPK signaling. a, b Expression of WT1-AS and WT1 determined by real-time PCR in HepG2 and 97H cells treated with doxorubicin (DOX) at concentration of 25, 50, 100, 200 ng/m. c Cell apoptosis determined detected by PI-Annexin V staining assay for 97H and HepG2 treated with either WT1-AS and shRNA targeting WT1. d Determination of DOX IC50 on 97H and HepG2 cells treated as indicated in the figure (upper panel). Expression of WT1, Caspase 3, and MDR1 in both 97H and HepG2 cells transfected with either WT1-AS and shRNA targeting WT1 and further treated with or without DOX at concentration of 75 ng/mL (lower panel). e Expression of WT1, p-STAT3, STAT3, p-MAPK, MAPK and Bcl-2 in 97H, HepG2 as well as their siWT1 treated cells treated with various concentration of DOX indicated in the figure. f Cell apoptosis determined detected by PI-Annexin V staining assay for 97H and HepG2 cell treated with various conditions indicated in the figure. All data presented as mean ± sd, N.S., No significance, ** indicated P < 0.01 by unpaired Student’s t test